Adjuvant chemotherapy in the elderly: Whom to treat, what regimen?

Oncologist

Volumn 11, Issue 3, 2006, Pages 234-242

  Burdette Radoux, Susan ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Aged; Chemotherapy, adjuvant; Neoplasms; Risk assessment

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; UFT; VINBLASTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ALGORITHM; ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ELDERLY CARE; FATIGUE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HORMONAL THERAPY; HUMAN; INFECTION; KIDNEY DISEASE; LIFE EXPECTANCY; LIFESPAN; LUNG NON SMALL CELL CANCER; METASTASIS; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RELAPSE; REVIEW; RISK ASSESSMENT; STOMATITIS; TREATMENT OUTCOME;

AGED; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMORBIDITY; GERIATRIC ASSESSMENT; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; NEOPLASMS; RISK ASSESSMENT;

EID: 33645062937     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-3-234     Document Type: Review

References (65)

1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-1283.
2. National Center for Health Statistics. Life Tables of the United States, 2002. Available at http://www.cdc.gov/nchs/data/dvs/life2002.pdf. Accessed September 26, 2005.
3. STAT!Ref Online Electronic Medical Library. Available at http://online.statref.com/document.aspx?fxid=8&docid=8736. Accessed January 17, 2006.
4. Yancik R, Wesley MN, Ries LA et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
5. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000;35:181-200.
6. Yancik R, Wesley MN, Ries LA et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998;82:2123-2134.
7. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
8. Doyle JJ, Neugut AI, Jacobson JS et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005;23:8597-8605.
9. Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-1332.
10. Schuchter LM, Hensley ML, Meropol NJ et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903.
11. Gelman RS, Taylor SG 4th Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404-1413.
12. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
13. Balducci L. Guidelines for the management of the older cancer patient. Cancer Treat Res 2005;124:233-256.
14. Shank WA Jr, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc 1992;40:151-154.
15. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Senior Adult Oncology, Version 1.2005. Available at http://www.nccn.org/professionals/physician_gls/PDF/ senior.pdf. National Comprehensive Cancer Network, Clinical Practice Guidelines. Accessed October 18, 2005.
16. National Heart, Lung and Blood Institute. The Cardiovascular Health Study (CHS). Available at http://128.208.129.3/chs. Accessed January 17, 2006.
17. Presant CA, Thompson E, Leberthon B et al. Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module: a pilot experience. Cancer 2005;103:2623-2628.
18. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003;114:180-187.
19. AdjuvantOnline.com. Adjuvant! for Breast Cancer (Version 8.0), © 2003-2006 Adjuvant! Inc. Available at http://www.adjuvantonline.com. Accessed January 17, 2005.
20. Olivotto IA, Bajdik C, Ravdin P et al. An independent population-based validation of the adjuvant decision-aid for stage I-II breast cancer. Proc Am Soc Clin Oncol 2004;22:8s.
21. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-1460.
22. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998;16:515-521.
23. McQuellon RP, Muss HB, Hoffman SL et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995;13:858-868.
24. Trimble EL, Carter CL, Cain D et al. Representation of older patients in cancer treatment trials. Cancer 1994;74(7 suppl):2208-2214.
25. Kemeny MM, Peterson BL, Kornblith AB et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-2275.
26. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
27. Benson AB 3rd, Pregler JP, Bean JA et al. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 1991;9:2067-2075.
28. Sateren WB, Trimble EL, Abrams J et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002;20:2109-2117.
29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
30. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001;(30):5-15.
31. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365.
32. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422.
33. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-1081.
34. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
35. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-1717.
36. Fargeot P, Bonneterre J, Roche H et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004;22:4622-4630.
37. Schrag D, Cramer LD, Bach PB et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857.
38. Potosky AL, Harlan LC, Kaplan RS et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002;20:1192-1202.
39. Ayanian JZ, Zaslavsky AM, Fuchs CS et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003;21:1293-1300.
40. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002;20:3992-3998.
41. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
42. Stein BN, Petrelli NJ, Douglass HO et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
43. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
44. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
45. Diaz-Rubio F, Burris H 3rd, Douillard JY et al. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). J Clin Oncol 2004;22(14 suppl):258s.
46. Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282-289.
47. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
48. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
49. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
50. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22(14 suppl):621s.
51. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
52. Charlson ME, Pompei P, Ales KL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
53. Miller MD, Paradis CF, Houck PR et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-248.
54. Desai MM, Bogardus ST Jr, Williams CS et al. Development and validation of a risk-adjustment index for older patients: the high-risk diagnoses for the elderly scale. J Am Geriatr Soc 2002;50:474-481.
55. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med 2002;18:737-757.
56. Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull 1988;24:609-614.
57. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142-148.
58. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-M156.
59. Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691-1699.
60. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
61. Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology (Williston Park) 2001;15:1567-1577, 1580; discussion 1581, 1586, 1591.
62. Patrick-Miller LJ, Broccoli TL, Much JK et al. Validation of the Distress Thermometer: a single item screen to detect clinically significant psychological distress in ambulatory oncology patients. J Clin Oncol 2004;22(14 suppl):525s.
63. Lachs MS, Feinstein AR, Cooney LM Jr et al. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 1990;112:699-706.
64. Extermann M, Meyer J, McGinnis M et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004;49:69-75.
65. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.